Resepmpasi
Nutrition

Dietary Supplements Face Scrutiny Over Hype, Safety and Product Quality

Written Oct 27, 2026 Audience 771 Author Michael Greger M.D. FACLM

Research finds supplement industry press releases often spin weak results, while limited oversight leaves consumers exposed to mislabeled or contaminated products.

Dietary Supplements Face Scrutiny Over Hype, Safety and Product Quality

The supplement industry’s public messaging can stay favorable even when clinical evidence points to no benefit or possible harm. At the same time, the scale of the U.S. market makes it difficult to ensure products match their labels. Together, those findings raise a practical question: how much confidence should consumers place in supplement claims and quality assurances?

Industry messaging can outlast the evidence

Research examining press releases from supplement industry trade organizations found that every release studied used “spin”—strategies that hype or diminish clinical findings. More than 90% of studies reporting no benefit or harm were followed by industry press releases that still advocated supplement use. The results are discussed in the video Supplementation Regulation and Side Effects: Efforts to Suppress the Truth.

The pattern matters because press releases shape how research reaches the public. The researchers argued that industry messaging may help sustain enthusiasm for supplements despite growing evidence of ineffectiveness and, in some cases, harm. Yet evidence from independent institutions may have limited influence on users: most supplement consumers surveyed said taxpayer-funded research contradicting manufacturers’ claims would affect them only minimally. Only about one in four said they would stop taking a supplement if public health authorities called it a waste of money.

That resistance can leave people paying for products that don’t help—or may make them ill. The broader problem of exaggerated medical messaging isn’t unique to supplements: studies have found overstatement in press releases from medical centers, journals and pharmaceutical companies. But the supplement trade groups’ responses described in this research show how favorable claims can persist even when study results are negative.

Oversight struggles to cover the market

The phrase “snake oil salesman” traces back to a real figure: Clark “the Rattlesnake King” Stanley. In 1916, investigators found that his supposed snake oil contained no snake oil; it was essentially moth repellent mixed with turpentine. Stanley was prosecuted under the Pure Food and Drug Act and fined $20.

Today, U.S. regulators face a much larger task. The Food and Drug Administration estimates that more than 85,000 dietary supplement products are sold in the country. Laws govern the industry, but the sheer number of products, underreported adverse effects, challenges in prosecuting violations and the ability to rebrand products removed from shelves all make oversight difficult.

One estimate puts supplement-related emergency room visits at 23,000 a year. Product contents can also differ from labels: supplements may lack the advertised ingredient or contain undisclosed substances. Prescription drugs cause serious harm and deaths as well, but that doesn’t make preventable supplement-related injuries less consequential.

Testing claims deserve scrutiny, too. Some products are adulterated with undeclared pharmaceuticals, especially those marketed for erectile dysfunction, weight loss, diabetes and high blood pressure. Third-party certification may offer some reassurance, but a practice known as “dry labbing” involves quality-control labs approving fabricated documents rather than conducting genuine checks.

The BMPEA case and its chilling effect

A dispute over β-methylphenylethylamine (BMPEA), a stimulant resembling amphetamine, shows the risks researchers can face when they investigate supplement ingredients. A Harvard researcher published work replicating earlier FDA findings that BMPEA appeared in several supplements sold in the United States.

Hi-Tech Pharmaceuticals, which makes weight-loss products including Black Widow and Yellow Scorpion, sued the researcher for libel, slander and product disparagement. The company initially sought $200 million in damages. STAT reported that the company’s head openly acknowledged hoping to “silence this guy.” The lawsuit ultimately failed, but reporting on the case described its potential to deter other academics from studying the industry. Hi-Tech’s CEO was reported to have said he hoped the costly legal battle would scare other researchers away.

For industry professionals, the case highlights a gap between a product’s public claims and the evidence available to verify them. High product volumes, uneven testing and pressure on researchers can make it harder for consumers and health professionals to distinguish reliable products from those that carry avoidable risks.

Doctor’s Note

The related video is Spin Doctors: How the Media Reports on Medicine.

Further coverage of supplement safety and oversight:

STAT, the medical journalism site cited above, is available here.

Source: Michael Greger M.D. FACLM · nutritionfacts.org

Discussion

Sign in to join the discussion.